Precision-by-design nanotherapeutics: integrating molecular modeling, systems biology, and targeted drug delivery for next-generation personalized medicine.
Li Yanhui Y, Pal Roy Samaresh S, Roy Kalyan K, Kumar Arun A et al.
Nanotherapeutics offer significant potential for targeted drug delivery, controlled release, and molecularly directed treatment, but their development remains challenged by biological heterogeneity, formulation complexity, reproducibility, scale-up, and limited translation from experimental to clinical settings. This review proposes Precision-by-Design (PbD) as an emerging conceptual framework that extends established Quality-by-Design (QbD) principles by incorporating patient- and disease-related biological information into nanotherapeutic development. The framework integrates systems biology, multi-omics data, molecular modelling, computational formulation analysis, and targeted drug-delivery engineering to support biologically informed development decisions. Molecular modelling is considered at both drug-target and drug-carrier levels, including molecular interactions, nanocarrier organisation, stability, biological interfaces, and release mechanisms. Systems biology approaches are discussed for biomarker identification and patient stratification, with potential implications for formulation attributes. A HER2-positive breast cancer example illustrates how molecular information could theoretically guide investigation of target selection and formulation variables, including ligand density, particle size, surface characteristics, drug loading, and release behaviour. Importantly, PbD is not an established clinical formulation methodology, and its proposed benefits require experimental, preclinical, and clinical validation. Future research should emphasise model validation, standardised characterisation, clinically relevant performance measures, regulatory integration, and prospective evaluation of PbD-guided nanotherapeutic development.